DELIVERY IN ECLAMPSIA: CAESAREAN VS VAGINAL DELIVERY
Main Article Content
Keywords
Abstract
OBJECTIVE: Compare the modes of delivery caesarean section and vaginal delivery in the management of eclampsia in terms of maternal, fetal outcome. STUDY DESIGN: This is a comparative prospective study. SETTING: The study entitled “Maternal and Fetal Outcome in Eclampsia: Caesarean Vs Vaginal Delivery” was done in M.K.C.G. Medical College & Hospital, Berhampur. The study period extended from October 2019 to August 2021. MATERIAL AND METHODS: The 210 patients of eclampsia were studied by dividing them into two groups . The first group consisted of patients in whom conservative obstetric management and delivery per vaginum was carried out and was called the “V.D. group” and the second group consisted of patients in whom lower segment caesarean section was carried out due to eclampsia and varied associated complications of eclampsia, unfavourable cervix, failed induction and was called the “ C.S. group”. CONCLUSION: Maternal and perinatal morbidity and mortality were low in patients undergoing caesarean delivery than in vaginal delivery group. Both maternal and perinatal outcome can be improved by taking an early decision for caesarean section when on admission cervix is unfavourable or delivery is not anticipated within 6 hours.
Downloads
References
1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article] 2. Gardiner SM, Kemp PA, March JE, Bennett T: Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol. 1994 Jul;112(3):823-30. [Article] 3. Gupta SK, Saxena A, Singh U, Arya DS: Bosentan, the mixed ETA-ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion. Mol Cell Biochem. 2005 Jul;275(1-2):67-74. [Article] 4. Marano G, Palazzesi S, Bernucci P, Grigioni M, Formigari R, Ballerini L: ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared carotid arteries of rabbits. Life Sci. 1998;63(18):PL259-66. [Article] 5. Turkan D, Yaman ME, Atila A, Kadioglu Y. Stability Indicating RP-HPLC Method Development and Validation for Bosentan in Pharmaceutical Formulations JOTCSA. 2022; 9(2): 505-512 6. Shahul HM, Jat RK, Indulatha VN. Method development and its validation for quantitative determination of bosentan in tablet dosage form by RP-HPLC. J Drug Delivery Ther. 2017 Mar 15;7(2):85–95. . 7.Lausecker, B., Hess, B., Fischer, G., Mueller, M., Hopfgartner, G. (2000). “Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection”. .J Chromatography B 749: 67. 8. Lausecker, B., Hopfgartner, G. (1995). “Determination of an endothelin receptor antagonist in human plasma by narrow-bore liquid chromatography and ionspray tandem mass spectrometry “. J Chromatography A 712: 75. 9. Sethi P.D., HPLC-Quantitative analysis of pharmaceutical formulations; 3rd edition, CBS publishers & distributors, 1997, Pg: 182. 9. Sharma B.K., Instrumental Methods of Chemical Analysis, GOEL Publication House, Meerut, Pg. 133-161, 68-80, 114-165, 286-320. 10. 10. Snyder.R, J. Kirkland, L. Glajch, Practical HPLC method development, 1997, II edition, A Wiley International publication, Pg: 235, 266-268, 351-353, 653-600, 686-695. 11.F.D.A. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center of Veterinary Medicine (CVM) Guidance for Industry: Bio-Analytical Method Validation; 2018 12. F.D.A. U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center of Veterinary Medicine (CVM) Guidance for Industry: Bio-Analytical Method Validation; 2013
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.